Skip to content
Screener

Cytokinetics CYTK Current Debt

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.03B-78.2%
Eli Lilly logo
Eli LillyLLY
$7.05B+23.2%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$0
Medtronic logo
MedtronicMDT
$1.79B-37.8%
ITG
Integer HoldingsITGR
$0-100%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217

FAQ

What is Cytokinetics's current debt?
Cytokinetics (CYTK) reported current debt of $27.36M in Q2 2026.
How has Cytokinetics's current debt changed year-over-year?
Cytokinetics's current debt increased by 90.0% year-over-year, from $14.4M to $27.36M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Cytokinetics's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude